What NovaBridge Biosciences does.

We are a global biotechnology platform company dedicated to bringing paradigm-shifting innovative treatments to the global markets in an accelerated and capital efficient manner. Since our inception, we have built a track record of identifying and developing novel and highly differentiated therapeutics worldwide. Leveraging our international infrastructure and industry-leading capabilities, we have established a distinctive value-creating platform to deliver innovation from emerging biopharma ecosystems to patients globally, while driving sustainable growth for shareholders.

Our innovative immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Our core product, givastomig, is a potential best-in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies. Givastomig is being studied in a recently initiated global randomized, Phase 2 study in combination with nivolumab and chemotherapy versus nivolumab and chemotherapy in first-line metastatic gastric cancer. Givastomig is also being studied in an ongoing Phase 1b study in combination with nivolumab and chemotherapy in first-line gastric cancer. We provided an update on the dose expansion cohorts of the Phase 1b study in January of 2026, and we expect to provide further updates in the second half of 2026 at a medical conference. We anticipate launching additional studies in other Claudin 18.2-positive gastrointestinal malignancies during 2026. In connection with our 2025 Realignment Plan, we have paused internal development of uliledlimab while we await further data from TJ Biopharma’s ongoing, randomized Phase 2 study combining uliledlimab with a checkpoint inhibitor in China. The results of these studies will help inform any potential future development path of uliledlimab. Our third program, ragistomig, is managed by our collaboration partner, ABL Bio, who is currently conducting an ongoing Phase 1 study in multiple solid tumors.

Revenue and profit, by fiscal year.

More on NBP.

• NovaBridge Biosciences summary
• NovaBridge Biosciences financial statements
• NovaBridge Biosciences key metrics
• NovaBridge Biosciences health scores and style box
• NovaBridge Biosciences earnings
• NovaBridge Biosciences dividends
• NovaBridge Biosciences valuation
• NovaBridge Biosciences ownership and insiders
• NovaBridge Biosciences peers

Figures from NovaBridge Biosciences's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.